First there was Botox, then there was Dysport, and now there is Xeomin. The FDA recently approved this new botulinum toxin type A product, Xeomin, from Merz Pharmaceuticals.

The Medesthetic Center is among the first aesthetic offices in the United States to receive Xeomin for cosmetic use beginning November 1st, 2011, and is providing these treatments at discounted prices, until March 2012, when Xeomin becomes available throughout the U.S.

“By being selected to offer this cutting edge product to our clients as early as possible, the Medesthetic Center is once again at the forefront of the latest advancement in skin treatment”, said Dr. George Zuzukin, Owner and Medical Director of the Medesthetic Center. ”Xeomin will be available around the United States beginning in the spring of 2012, so we are thrilled to be able to offer it to our clients immediately”!

See the FDA Approval Notice Here